RNS: Cipla has introduced Afrezza, India’s first inhalable insulin, following approval from the Central Drugs Standard Control Organisation (CDSCO). Developed by MannKind Corporation in the USA, Afrezza offers a needle-free, rapid-acting insulin option for managing diabetes.
This groundbreaking product targets improved glycemic control for adults with type 1 and type 2 diabetes, particularly those who face challenges with injectable insulin therapies. Afrezza is delivered via a small inhaler, providing a convenient, non-invasive alternative for individuals with needle aversion.
Cipla’s launch of Afrezza in India marks a major advancement in diabetes care, offering a new option in a country with one of the highest diabetes burdens in the world.
